Interferon-α-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule

Clinical Cancer Research

Volumn 5, Issue 10, 1999, Pages 2726-2734

  Slaton, Joel W ^a   Perrotte, Paul ^a   Inoue, Keiji ^a   Dinney, Colin P N ^a   Fidler, Isaiah J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; GELATINASE B; INTERLEUKIN 8; MESSENGER RNA; VASCULOTROPIN;

ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; GENE REPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON ALFA-2A; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0032719528     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Isaacs, A., and Lindenmann, J. Virus interference. I. The interferon. Proc. R. Soc. Lond., 147: 258-267, 1957.
2. Baron, S., and Dianzani, F. The interferons: a biological system with therapeutic potential in viral infections. Antiviral Res., 24: 97-110, 1994.
3. Hertzog, P. J., Hwang, S. Y., and Kola, I. Role of interferons in the regulation of cell proliferation, differentiation, and development. Mol. Reprod. Dev., 39: 226-232, 1994.
4. Gutterman, J. U. Cytokine therapeutics: lessons from interferon-α. Proc. Natl. Acad. Sci. USA, 91: 1198-1205, 1994.
5. Krown, S. E. Interferons in malignancy: biological products or biological response modifiers? J. Natl. Cancer Inst., 80: 306-309, 1988.
6. Thomas, H., and Balkwill, F. R. Effects of interferons and other cytokines on tumors in animals: a review. Pharmacol. Ther., 52: 307-314, 1991.
7. Singh, R. K., Bucana, C. D., Gutman, M., Fan, D., Wilson, M. R., and Fidler, I. J. Organ-site dependent expression of bFGF in human renal cell carcinoma cells. Am. J. Pathol., 145: 365-374, 1994.
8. Singh, R. K., Llansa, N., Bucana, C. D., Sanchez, R., Koura, A., and Fidler, I. J. Cell density-dependent regulation of basic fibroblast growth factor expression in human renal cell carcinoma cells. Cell Growth Differ., 7: 397-404, 1996.
9. Singh, R. K., Bucana, C. D., Llansa, N., Sanchez, R., and Fidler, I. J. Cell density-dependent modulation of basic fibroblast growth factor expression by human interferon-β. Int. J. Oncol., 8: 649-656, 1996.
10. Vermeulen, P. B., Diriz, L. Y., Martin, M., Lemmens, J., and Van Oosterom, A. T. Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon-α-2b. J. Natl. Cancer Inst., 89: 1316-1317, 1997.
11. Oliveira, I. C., Sciavolino, P. J., Lee, T. H., and Vilcek, J. Down-regulation of interleukin-8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition of interferon. Proc. Natl. Acad. Sci. USA, 89: 9049-9053, 1992.
12. Singh, R. K., Gutman, M., Llansa, N., and Fidler, I. J. Interferon-β prevents the upregulation of interleukin-8 expression in human melanoma cells. J. Interferon Cytokine Res., 16: 577-584, 1996.
13. Van Damme, J., and Opdenakker, G. Interaction of interferons with skin reactive cytokines: from interleukin-1 to interleukin-8. J. Investig. Dermatol., 95: 90S-93S, 1990.
14. Fabra, A., Nakajima, M., Bucana, C. D., and Fidler, I. J. Modulation of the invasive phenotype of human colon carcinoma cells by fibroblasts from orthotopic or ectopic organs of nude mice. Differentiation, 52: 101-110, 1992.
15. Gohji, K., Fidler, I. J., Tsan, R., Radinsky, R., von Eschenbach, A. C., Tsuruo, T., and Nakajima, M. Human recombinant interferons p and γ decrease gelatinase production and invasion by human KG-2 renal carcinoma cells. Int. J. Cancer, 58: 380-384, 1994.
16. Kato, N., Nawa, A., Tamakochi, K., Kikkawa, F., Suganuma, N., Okamoto, T., Goto, S., Tomoda, Y., Hamaguchi, M., and Nakajima, M. Suppression of gelatinase production with decreased invasiveness of choriocarcinoma cells by human recombinant interferon-β. Am. J. Obstet. Gynecol., 172: 601-606, 1995.
17. Bulbul, M. A., Huben, R. P., and Murphy, G. P. Interferon-beta treatment of metastatic prostate cancer. J. Surg. Oncol., 33: 231-233, 1986.
18. Schiller, J. H., Storer, B., Bittner, G., Willson, J. K., and Borden, E. C. Phase II trial of a combination of interferon-β ser and interferon-γ in patients with advanced malignant melanoma. J. Interferon Res., 8: 581-589, 1988.
19. Einhorn, S., and Grander, D. Why do so many cancer patients fail to respond to interferon therapy? J. Interferon Cytokine Res., 16: 275-281, 1996.
20. Ozzello, L., Habif, D. V., and DeRosa, C. M. Antiproliferative effects of natural interferon-β alone and in combination with natural IFN-γ on human breast carcinomas in nude mice. Breast Cancer Res. Treat., 16: 89-96, 1990.
21. Strander, H. Interferon treatment of human neoplasia. Adv. Cancer Res., 46: 1-26, 1991.
22. Dianzani, F. Interferon treatments: how to use an endogenous system as a therapeutic agent. J. Interferon Res., Special Issue: 109-118, 1992.
23. Salmon, P., LeCotonnec, J. Y., Galazka, A., Abdul-Ahad, A., and Darragh, A. Pharmacokinetics and phannacodynamics of recombinant human interferon-β in healthy male volunteers. J. Interferon Cytokine Res., 16: 759-764, 1996.
24. Dinney, C. P. N., Fishbeck, R., Singh, R. K., Eve, B., Pathak, S., Brown, N., Xie, B., Fan, D., Bucana, C. D., Fidler, I. J., and Killion, J. J. Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J. Urol., 54: 1532-1538, 1995.
25. Dinney, C. P. N., Bielenberg, D. R., Perrotte, P., Reich, R., Eve, B. Y., Bucana, C. D., and Fidler, I. J. Inhibition of basic fibroblast growth factor expression, angiogenesis and growth of human bladder carcinoma in mice by systemic interferon-α administration. Cancer Res., 58: 808-814, 1998.
26. Vecchi, A., Garlanda, C., Lampugnami, M. G., Resnati, M., Matteucci, C., Stopacciaro, A., Schnurch, H., Risau, W., Ruco, L., Mantovani, A., and Dejana, E. Monoclonal antibodies specific for endothelial cells of mouse blood vessels: their application in the identification of adult and embryonic endothelium. Eur. J. Cell Biol., 63: 247-254, 1994.
27. Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J. Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N. Engl. J. Med., 324: 1-8, 1991.
28. Yoneda, J., Kuniyasu, H., Crispens, M. A., Price. J. E., Bucana, C. D., and Fidler, I. J. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J. Natl. Cancer Inst., 90: 447-454, 1998.
29. Park, C-S., Manahan, L. J., and Brigati, D. J. Automated molecular pathology: one hour in situ DNA hybridization. J. Histotechnol., 14: 219-229, 1991.
30. Caruthers, M. H., Beaucage, S. L., Efcavitch, J. W., Fisher, E. F., Goldman, R. A., Dehaseth, P. L., Mandechi, W., Matteucci, M. D., Rosendahl, M. S., and Stabinsky, Y. Chemical synthesis and biological studies on mutated gene-control region. Cold Spring Harbor Symp. Quant. Biol., 47: 411-418, 1982.
31. Radinsky, R., Bucana, C. D., Ellis, L. M., Sanchez, R., Cleary, K. R., Brigati, D. J., and Fidler, I. J. A rapid colorimetric in situ messenger RNA hybridization technique for analysis of epidermal growth factor receptor in paraffin-embedded surgical specimens, of human colon carcinomas. Cancer Res., 53: 937-943, 1993.
32. Kitadai, Y., Ellis, L. M., Tucker, S. L., Greene, G. F., Bucana, C. D., Cleary, K. R., Takahashi, Y., Tahara, E., and Fidler, I. J. Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma. Am. J. Pathol., 149: 1541-1551, 1996.
33. Reed, J. A., Manahan, L. J., Park, C. S., and Brigati, D. J. Complete one-hour immunocytochemistry based on capillary action. Biotechniques, 13: 434-443, 1992.
34. Kuniyasu, H., Ellis, L., Evans, D. B., Abbruzzese, J. L., Fenoglio, C. J., Bucana, C. D., Cleary, K. R., Tahara, E., and Fidler, I. J. Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clin. Cancer Res., 5: 25-33, 1999.
35. Fisher, L. D., and van Belle, G. Biostatistics, pp. 786-843. New York: John Wiley & Sons, 1993.
36. Folkman, J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical application of research on angiogenesis. N. Engl. J. Med., 333: 1757-1763, 1995.
37. Fidler, I. J., and Ellis, L. M. The implications of angiogenesis to the biology and therapy of cancer metastasis. Cell, 79: 185-188, 1994.
38. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
39. Dvorak, H. F., Brown, L. F., Detmar, M., and Dvorak, A. M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol., 146: 1029-1039, 1995.
40. Singh, R. K., Gutman, M., Radinsky, R., Bucana, C. D., and Fidler, I. J. Cancer Res., 54: 3242-3246, 1994.
41. Koch, A. E., Friedman, J., Burrows, J. C., Haines, G. K., and Bouch, N. P. Localization of the angiogenesis inhibitor thrombospondin in human synovial tissues. Pathobiology, 61: 1-6, 1993.
42. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79: 315-328, 1994.
43. Sim, B. K., O'Reilly, M. S., Liang, H., Fortier, A. H., He, W., Madsen, J. W., Lapcevich, R., and Nacy, C. A. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res., 57: 1329-1334, 1997.
44. Dong, Z., Kumar, R., Yang, X., and Fidler, I. J. Macrophage-derived metalloelastase is responsible for the generation of angioslatin in Lewis lung carcinoma. Cell, 88: 801-810, 1997.
45. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1977.
46. Bouck, N., Stellmach, V., and Hsu, S. C. How tumors become angiogenic. Adv. Cancer Res., 69: 135-174, 1996.
47. Singh, R. K., Gutman, M., Bucana, C. D., Sanchez, R., Llansa, N., and Fidler, I. J. Interferons-α and -β downregulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl. Acad. Sci. USA, 92: 4562-4566, 1995.
48. Bielenberg, D. R., Fidler, I. J., and Bucana, C. D. Constitutive expression of interferon-β in differentiated epithelial cells exposed to environmental stimuli. Cancer Biother. Radiopharmaceut., 13: 375-382, 1998.
49. Bielenberg, D. R., Bucana, C. D., Sanchez, R., Mulliken, J. B., Folkman, J., and Fidler, I. J. Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of endogenous angiogenesis inhibitor, IFN-β. Int. J. Oncol., 14: 401-408, 1999.
50. Fidler, I. J. Critical factors in the biology of human cancer metastasis: twenty-eighth G. H. A. Clowes Memorial Award Lecture. Cancer Res., 50: 6130-6138, 1990.
51. Fidler, I. J. Modulation of the organ microenvironment for the treatment of cancer metastasis. J. Natl. Cancer Inst., 87: 1588-1592, 1995.
52. Gutman, M., Singh, R. K., Xie, K., Bucana, C. D., and Fidler, I. J. Regulation of IL-8 expression in human melanoma cells by the organ environment. Cancer Res., 55: 2470-2475, 1995.
53. Marshall, M. E., Wolf, M., Crawford, E. D., Thompson, I. M., Flanigan, R., Balcerzak, S. P., and Meyers, F. J. Evaluation of low dose α-interferon (Roferon-A) in patients with advanced renal cell carcinoma: a Southwest Oncology Group study. Cancer Biother., 10: 205-209, 1995.
54. Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., and Blum, R. H. Interferon α-2b adjuvant therapy of high risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol., 14: 7-17, 1996.
55. Baron, S., Tyring, S. K., Fleischmann, W. R., Jr., Coppenharer, D. H., Niesel, D. W., Klimpel, G. R., Stanter, G. J., and Hughes, T. K. The interferons. Mechanisms of action and clinical applications. J. Am. Med. Assoc., 266: 1375-1383, 1991.
56. Shepherd, F. A., Beaulieu, R., Gelmon, K., Thuot, C. A., Sawka, C., Read, S., and Singer, J. Prospective randomized trial of two dose levels of interferon-α with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study. J. Clin. Oncol., 16: 1736-1742, 1998.
57. Fossa, S., Jones, M., Johnson, P., Joffe, J., Holdener, E., Elson, P., Ritchie, A., and Selby, P. Interferon-α and survival in renal cell carcinoma. Br. J. Urol., 76: 286-290, 1995.
58. Legha, S. S. The role of interferon α in the treatment of metastatic melanoma. Semin. Oncol., 24: S4-24-S4-34, 1997.
59. Logothetis, C. J., Hossan, E., Recondo, G., Sella, A., Ellerhorst, J., Kilbourn, R., Zukiwski, A., and Amato, R. 5-Fluorouracil and interferon-α in chemotherapy refractory bladder carcinoma: an effective regimen. Anticancer Res., 14: 1265-1279, 1994.
60. Negrier, S., Escudier, B., Lasset, C., Douillard, J-Y., Savary, J., Chevreau, C., Ravaud, A., Mercatello, A., Peny, J., Mousseau, M., Philip, T., and Tursz, T. Recombinant human interleukin-2, recombinant human interferon-α-2a, or both in metastatic renal cell carcinoma. N. Engl. J. Med., 338: 1272-1278, 1998.
61. Fierlbeck, G., Ulmer, A., Schreiner, T., Stroebel, W., Schieble, U., and Brzoska, J. Pharmacodynamics of recombinant IFN-α during long-term treatment of malignant melanoma. J. Interferon Cytokine Res., 16: 777-781, 1996.
62. Johns, T. G., Mackay, I. R., Callister, K. A., Hertzog, P. J., Devenish, R. J., and Linnane, A. W. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon-β. J. Natl. Cancer Inst., 84: 1185-1190, 1992.
63. Rios, A., Mansell, P. W., Newell, G. R., Reuben, J. M., Hersh, E. M., and Gutterman, J. U. Treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma with lymphoblastoid interferon. J. Clin. Oncol., 3: 506-512, 1985.
64. Mitsuyasu, R. T. Interferon-α in the treatment of AIDS-related Kaposi's sarcoma. Br. J. Haematol., 79: 69-73, 1991.
65. Groopman, J. E., Gottlieb, M. S., Goodman, J., Mitsuyasu, R. T., Conant, M. A., and Prince, H. Recombinant α-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann. Intern. Med., 100: 671-676, 1984.
66. Real, F. X., Oettgen, H. F., and Krown, S. E. Kaposi's sarcoma and AIDS treatment with high and low doses of recombinant leukocyte A interferon. J. Clin. Oncol., 4: 544-551, 1986.
67. Ezekowitz, R. A. B., Mulliken, J. B., and Folkman, J. Interferon α-2a therapy for life-threatening hemangiomas of infancy. N. Engl. J. Med., 126: 1456-1463, 1992.
68. White, C. W., Sondheimer, H. M., Crouch, E. C., Wilson, H., and Fan, L. L. Treatment of pulmonary hemangiomatosis with recombinant interferon-α-2a. N. Engl. J. Med., 320: 1197-1200, 1989.
69. Orchard, P. J., Smith, C. M., Woods, W. G., Day, D. L., Dehner, L. P., and Shapiro, R. Treatment of haemangioendotheliomas with α-interferon. Lancet, 2: 565-567, 1989.
70. Ezekowitz, A., Mulliken, J., and Folkman, J. Interferon-α therapy of hemangiomas of infancy. Br. J. Haematol., 79: 67-68, 1991.
71. Ricketts, R. R., Hatley, R. M., Corden, B. J., Sabio, H., and Howell, C. G. Interferon-α-2a for the treatment of complex hemangiomas of infancy and childhood. Ann. Surg., 6: 605-614, 1994.
72. Sidky, Y. A., and Borden, E. C. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res., 47: 5155-5161, 1987.
73. Brouty-Boye, D., and Zetter, B. R. Inhibition of cell motility by interferon. Science (Washington DC), 208: 516-518, 1988.
74. Kaban, L. B., Mulliken, J. B., Ezekowitz, R. A., Ebb, D., Smith, P. S., and Folkman, J. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon α-2a. Pediatrics, 103: 1145-1149, 1999.
75. Nicholson, S. E., and Hilton, D. J. The SOCS proteins: a new family of negative regulators of signal transduction. J. Leukocyte Biol., 63: 665-668, 1998.
76. Narazaki, M., Fujimoto, M., Matsumoto, T., Morita, Y., Saito, H., Kajita, T., Yoshizaki, K., Naka, T., and Kishimoto, T. Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin-6 signaling. Proc. Natl. Acad. Sci. USA, 95: 13130-13134, 1998.
77. Liu, B., Liao, J., Rao, X., Kushner, S., Chung, C. D., Chang, D. D., and Shuai, K. Inhibition of Stat1-mediated gene activation of PIAS1. Proc. Natl. Acad. Sci. USA, 95: 10626-10631, 1998.